ArticleAnnals of surgical oncology2026
Is Surgery Necessary for Stage IVB Gastric Cancer Showing Clinical Complete Response to Chemotherapy or Systemic Cancer Therapy?
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognosis-predicting factor of gastrectomy after systemic cancer therapy for cStage IVB gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor stage IVB gastric cancer, recently, systemic cancer therapy (including cytotoxic chemotherapy, immune checkpoint inhibitors, and molecular targeted agents) is the standard treatment based on biomarker testing. If these treatments are successful and the tumor becomes resectable, conversion surgery may be considered, though its significance remains unclear. In cases showing clinical complete response (cCR), the necessity of surgery is further debated.
methodsThis retrospective single-center study included patients with cStage IVB gastric cancer who received chemotherapy or systemic cancer therapy, regardless of undergoing conversion surgery, between 2013 and 2023. Patients were stratified by objective tumor response on imaging (cCR or others). Those achieving cCR were further divided into two groups: non-OP (follow-up without surgery) and OP (underwent conversion surgery) for survival comparison.
resultsAmong 1591 patients treated with systemic chemotherapy, 51 (3.2%) achieved cCR (33 non-OP; 18 OP). In the cCR cohort, the median follow-up was 57 months. The 3-year overall survival (OS) was 97% in the non-OP group and 86% in the OP group (P = 0.44), respectively. Among the entire population, conversion surgery was performed in 121 patients (7.6%), in whom pathological CR (pCR) was seen in 17 (14%). This included 10 patients with cCR and seven without cCR. Three-year OS of pCR patients was 93%.
conclusionsThe results suggested the potential for long-term survival without surgery in patients showing cCR. However, further investigation is needed regarding accurate methods to assess tumor disappearance.
Indexed as
Identifiers
41168607What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.